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ABSTRACT
Objective The emergence of infectious diseases pose 
major global health threats. Estimates of total in- country 
human pathogen diversity, and insights as to how and 
when species were described through history, could 
be used to estimate the probability of new pathogen 
discoveries. Data from the Lao People’s Democratic 
Republic (Laos) were used in this proof- of- concept study 
to estimate national human pathogen diversity and to 
examine historical discovery rate drivers.
Methods A systematic survey of the French and English 
scientific and grey literature of pathogen description in 
Laos between 1874 and 2017 was conducted. The first 
descriptions of each known human pathogen in Laos were 
coded according to the diagnostic evidence available. 
Cumulative frequency of discovery across time informed 
the rate of discovery. Four distinct periods of health 
systems development in Laos were identified prospectively 
and juxtaposed to the unmodelled rate of discovery. A 
model with a time- varying rate of discovery was fitted to 
these data using a Markov- Chain- Monte- Carlo technique.
Results From 6456 pathogen descriptions, 245 
discoveries of known human pathogens in Laos, including 
repeat discoveries using different grades of evidence, 
were identified. The models estimate that the Laos 
human pathogen species diversity in 2017 is between 
169 and 206. During the last decade, there has been a 
33- fold increase in the discovery rate coinciding with the 
strengthening of medical research and microbiology.
Conclusion Discovery curves can be used to model and 
estimate country- level human pathogen diversity present 
in a territory. Combining this with historical assessment 
improves the understanding of the factors affecting local 
pathogen discovery.
PROSPERO registration number A protocol of this work 
was registered on PROSPERO (ID:CRD42016046728).
INTRODUCTION
Human pathogens are defined as species- level 
organisms associated with disease or clinical 
infection in humans.1 In 2007, a total of 1399 
human pathogen species were described glob-
ally.1 As far as we are aware there are no maps 
of variation in national human pathogen 
species richness, nor predictions of how many 
pathogens may be present but have not yet 
been described, globally or in nation states.
The emergence and re- emergence of 
human pathogens is influenced by numerous 
demographic, historical, sociological, popula-
tion and environmental factors.2 An increase 
in spill- over events has prompted research 
to develop new tools and methodologies for 
Key questions
What is already known?
 ► Discovery curves have been used to estimate the di-
versity of diverse taxa such as trees, ants, birds and 
ferns. They have also been used to estimate global 
virus species diversity.
 ► Estimates of country- level pathogen diversity are 
needed to inform policy on potential of emergence, 
guide appropriate investment of resources in the 
skills, facilities and technologies necessary for ae-
tiological discovery, particularly in resource limited 
setting like Laos.
 ► A historical analysis of the local context is needed 
to build on past experience of pathogen discovery to 
identify factors that facilitate discovery and encour-
age appropriate investment.
What are the new findings?
 ► From 6455 pathogen description records, 244 first 
descriptions of known human pathogens in Laos, in-
cluding repeat discoveries using different grades of 
evidence, were identified.
 ► Four distinct periods of health systems in Laos were 
prospectively identified and juxtaposed to the un-
modelled rate of discovery.
 ► The models estimate that the human pathogen spe-
cies diversity in 2017 in Laos was between 169 and 
206.
 ► A 33- fold increase in the discovery rate was ob-
served during the last decade, reflecting greatly in-
creased investment in medical research.
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estimating pathogen diversity. There are many methods 
of varying complexity and associated criticisms for esti-
mating species diversity.3–9 The work of the Global 
Virome Project and others aims to estimate viral diversity 
to help predict outbreaks, of striking importance in the 
face of the current pandemic.10 However, such work is 
costly and requires large- scale host sampling. Here, we 
use existing historical records and discovery curve theory 
to investigate how many of the globally described human 
pathogens affect the people of the Lao People’s Demo-
cratic Republic (Laos).
Discovery curves have been used to estimate the global 
diversity of diverse taxa such as trees, ants, birds, ferns 
and viruses.3–5 The method extrapolates from the frac-
tion of species known to exist in a designated area using 
the rate of discovery of new species over time and prop-
agating that forward into the future until a maximum is 
reached.3 11 12 As far as we are aware, the use of discovery 
curves to estimate total country- level human pathogen 
diversity has not yet been attempted.
Laos is a small mountainous land- linked country 
(~237 955 km2), bordered by Thailand and Myanmar to 
the west, Vietnam to the east, China to the north and 
Cambodia to the south. Laos’ population is approaching 
7 million; the rural population comprises 49 recognised 
ethnic groups reflecting the social and cultural hetero-
geneity of the region.13 14 The widespread consumption 
of wild vertebrates in Laos as ‘bushmeat’ and limited 
rural diagnostic infrastructure increases the likelihood of 
occurrence, but not the discovery, of zoonotic spill- over 
events.15 Poverty, consumption practises and extreme 
climates underlie the myriad of diseases that exist in this 
region.16 17
This paper contributes to the ongoing literature on 
methods for estimating species diversity4 5 and used time- 
varying rate discovery curve modelling of the rate of 
description of human pathogens in Laos, using Markov- 
Chain- Monte- Carlo (MCMC) methods, to estimate the 
total number of human pathogens currently in Laos 
and understand the historical influences on changes in 
pathogen within- country discovery rate.
METHODS
Data on human pathogen species and their year of 
discovery were used to inform the model’s discovery rate. 
Laos history was categorised into four different phases of 
health systems to examine changing historical contexts 
affecting discovery rates (below, online supplemental 
file, table 1).8
Search strategy, selection criteria and data structure
As no prior synthesis of the description of human patho-
gens in Laos was available, a systematic review, using the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses guidelines, was conducted (online supple-
mental file, figure 1). Databases were searched using 
both French and English search terminology. An iterative 
search of the grey literature was conducted in Vientiane, 
Laos, in the Lao Department of National Archives, the 
National Library, the École française d'Extrême- Orient, 
WHO Laos National Office library, University of Health 
Sciences and in Bangkok, Thailand at Mahidol University 
and in Aix- en- Provence, France, the Archives Nationales 
d’Outre- Mer. Published e- journals, grey literature and 
databases were searched of PubMed, the London School 
of Hygiene and Tropical Medicine library, the South East 
Asian Journal of Tropical Medicine and Public Health 
and the Korean Journal of Parasitology and Oxford 
University databases. The search included publications 
from 1866, the first French exploration into Laos, and 
papers published prior to 31 December 2017. Informa-
tion on disease occurrence using scientific names prior 
to French colonisation was not found.
All documents referencing the discovery and/or inci-
dence of human pathogens and diseases reported or 
sampled from Laos were considered, whether in humans, 
vectors or reservoirs. Documents and searches written in 
Lao script were excluded due to limited medical standard-
isation of disease terminology within the language.18 The 
following broad English search terms and their variants 
were included [“health” OR “medicine” OR “disease” 
OR “epidemiology” OR “pathology”] AND [“Lao” OR 
“Laos”] AND [“first” OR “discovery” OR “isolate”]. The 
following broad French search terms and their variants 
were included [“santé” OR “pathologie” OR “mede-
cine” OR “maladie” OR “épidémiologie”] AND [“Lao” 
OR “Laos”]. The grey literature (hospital and medical 
reports, textbooks and correspondence) that dominated 
the French language search, meant it was necessary to 
include not only pathogens identified by authors as first 
descriptions but also those that we suspected were the 
first descriptions. In addition, to the systematic electronic 
and manual searches, references were manually searched 
when reports were located.
‘Early’ (the period pre- 1990s) national health reports, 
accounts from medical personnel, case reports, journals, 
Key questions
What do the new findings imply?
 ► Our finding show that it is possible, with sparse and historically 
varied infectious disease surveillance, to model pathogen discov-
ery and estimate pathogen species diversity The time- varying rate 
discovery curve model is a useful proof- of- concept to estimate how 
many pathogens may be present in territories with sparse infec-
tious disease surveillance and can be tested prospectively. This 
type of analysis could be used to guide appropriate investment in 
resources necessary for aetiological discovery, especially in scarce- 
resource settings
 ► Country- level historically linked discovery curve investigations 
elsewhere could improve our understanding of pathogen diversity 
between countries and estimate the probabilities of new discover-
ies and our understanding of the factors influencing such discover-
ies in different health systems.
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theses and other published documents were searched. 
Only paper health reports from pre-1990 were included 
as reports after then could be assumed to be identified 
through internet searches. Using Adobe Professional 
(V.16.12.13, Adobe Systems) documents were converted 
into readable- text- format and searched according to the 
search strategy. Mendeley (Mendeley Desktop 1.16.1, 
Mendeley) was used to manage references. Uncertain 
entries were re- examined by PN, TR and collaborators 
(see the acknowledgements).
Every human pathogen referenced in the source docu-
ments was given a new line item in the dataset and accom-
panied by variables for the date of identification and 
publication, the source and type of document it came 
from and a measure of certainty in the diagnosis. Patho-
gens are defined as potential causes of human disease 
and are listed in Laos irrespective as to whether they were 
described as causing disease. Three grades of evidence 
were used to stratify the dataset into measures of certainty 
in the discovery specificity.
Grade 1 includes culture and/or molecular assays 
(which includes PCR diagnosis) and/or direct micro-
scope observation, grade 2 is serology- based diagnosis 
and grade 3 a clinical diagnosis without aetiological labo-
ratory assays. For most pathogens, grade 3 represents 
the lowest grade of diagnostic confidence available. 
The perceived prestige of being the first to identify the 
presence of a pathogen in Laos may lead to confirma-
tion bias and the graded data helps to account for this.19 
Under the stratified grading system, the first description 
was for each the grade of evidence that was used for the 
diagnosis.
Statistical and historical analysis
Discovery curves are used to estimate the total number 
of species in a specified area,3 11 12 20 such as used for 
the diversity of human viral species by Woolhouse et 
al.1 11 12 21 22 Discovery curves require that organism 
taxonomy is generally accepted and assumes that the 
number of organisms available for discovery is finite.3 
Hence, as discovery saturates the number of known 
species approaches the number of existing species.
The geographical region is defined by Laos’ borders 
that have remained relatively unchanged since the 1893 
Siam- France treaty, when Siam (modern Thailand) 
surrendered territories east of the Mekong to France.23 
Only one data point, from the town Luang Prabang, was 
described prior to 1893 and is included in the dataset,24 
as the town was and remained part of Laos in that year 
and since.
Discovery curves comprised cumulative frequency plots 
of the identified organisms against their year of descrip-
tion.11 22 Curves were created by cumulatively plotting 
organisms against their year of discovery and using inter-
polation to smooth the results. Three diagnostic tech-
nique grade stratified curves formed the backdrop for 
historical discussion (figure 1). These data were then 
used to develop three discovery curves of increasing diag-
nostic certainty.
The first discovery curve (level 3) used the minimum 
year value (earliest date) from the set containing all 
grade data. The second curve (level 2) the minimum year 
value from the set containing only grade 1 and 2 data. 
The final discovery curve (level 1) used only data from 
grade 1. Thus the three discovery curves, by incremen-
tally excluding lower quality graded evidence, reflected 
an increase of certainty in our estimate of pathogen 
diversity (see online supplemental file, figure 2).
Previous time- based discovery- curve analyses assumed a 
constant- rate of pathogen discovery. The historical discus-
sion supported a time- variant approach by suggesting 
four distinct periods of public health experienced in 
Laos; the French era of colonisation (1893–1953), the 
postcolonial (1953–1975), the socialist (1975–1990) 
and the post- Soviet periods (1990 to the present).13 The 
impact of historical events and changing pathogen diag-
nostic capabilities are functionally unaccounted for if 
a constant rate of discovery is assumed. We developed 
a model that used a historical discussion to inform the 
changing rate of discovery for the years 1873–2017. The 
model defines the expected number of discovered patho-













The total number of species available for discovery is 
given by the parameter  N. Therefore, when interpreting 
the model estimate of N to answer the question, ‘how 
many species of pathogens are there in Laos?’ the sum of 
Figure 1 The cumulative frequency of human pathogen 
discovery in Laos for the period 1874–2017, stratified by 
the grade of evidence used to identify the pathogens, in 
which grade 1 represents either culture, direct observation, 
molecular (which includes PCR diagnosis) or direct 
microscope observation, grade 2 is serological diagnosis and 
grade 3 is clinical diagnosis.
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pathogens found prior to  t = 1  c , is added to the estimate. 
The question posed is answered by  N+ c .
The probability of discovery at time  t  is given by param-














Where the parameters  a, k  and  k2  allow for a sigmoidal 
increase in the probability of discovery and  f   represents 
the fold increase of the second inflection point in the 
rate of discovery. Thus, in this model, the discovery rate 
changes from its baseline value to a new value at time  k  
and  k2 .
The parameters were fitted to the data using MCMC 
Bayesian inference simulation with a standard Metropolis- 
Hastings parameter sampling algorithm adjustment and 
a 5000- iteration burn- in period. The MCMC simulations 
were run for each level of evidence using 1 million runs. 
All parameters received uniform priors except  N  and 
 f   for which a normal prior distribution was considered 
reasonable. Mean parameter estimates (after burn- in) 
were used to compare it to the cumulative distribution of 
the observed data.
Confidence Intervals around the mean estimates were 
calculated using the 5th and 95th percentiles of the 
posterior distributions for each parameter. A sensitivity 
analysis was conducted using a 1000 bootstrap samples of 
the posterior parameter distributions (after burn- in) to 
reflect the estimated uncertainty around the mean esti-
mated model.
Patient and public involvement
Patients and/or the public were not involved in the 
design, or conduct, or reporting, or dissemination plans 
of this research.
RESULTS
The final pre- exclusion dataset consisted of 6456 entries 
and the final dataset comprised 5127 entries (figure 1). 
Each entry included year of discovery, organism name, 
assigned grade of evidence and reference to the source 
document (online supplemental file, table 1). After line 
items had been coded according to date of appearance 
for each grade, these data were further reduced to 244 
species- level discoveries, including repeat discoveries at 
different grades of evidence (for a complete list of first 
descriptions see online supplemental file, table 1). The 
final dataset spanned the period 1874–2017. No human 
pathogens have yet been described for the first time as 
new species to science in Laos.
The year of description and grade of evidence for each 
of the 244 identified species was used to develop the 
grade stratified figure 1, as well as the discovery curves 
in online supplemental file, figure 2; The shapes gener-
ated for grade 1 in these figures, even with deceleration 
in the discovery rate from 2013, do not suggest a clear 
trend towards an asymptote, indicating discovery has not 
yet saturated.
We fitted the time- varying discovery rate model to the 
cumulative curves in figure 1 to estimate the total number 
of existing pathogen species in Laos for each grade of 
evidence, using MCMC techniques (figures 2–4, table 1). 
As the observed sustained flattening of the curves in the 
postcolonial era (figure 1) could not be modelled, the 
models were restricted to years after 1953. The discov-
eries before 1954 were captured by a constant (ie  t  =1 is 
the year 1954). All the models and parameters closely fit 
the data with approximately normal distributions (figures 
3–4). Table 1 compares estimated parameters across the 
models. The estimates of 169 and 206 (table 1),  N + c
 , are the first approximations of pathogen diversity in 
Laos. Where  c  is the number of discovered pathogens at 
the 1954 time point, and  N  is the estimate derived from 
modelling the data post-1954. The fold increase,  f  , of the 
discovery rate following the last inflection are 33.99, 32.30 
and 34.83 for the levels 1, 2 and 3 models, respectively.
DISCUSSION
The changing diagnostic capabilities of Laos are reflected 
in the granularity of pathogen discoveries over time. The 
majority of human pathogens recorded from Laos to date 
are bacteria (online supplemental file, table 2). Bacterio-
logical techniques (grade 1) and limited serology (grade 
2) arrived in Laos in the late 19th century and began to 
replace clinical descriptions (grade 3), while recently the 
molecular technologies have begun to predominate in 
the literature (figure 1).25
Over the last 150 years Laos’ path of pathogen discovery 
has been disrupted by political unrest and conflict and 
undergone an ideological transformation from a loosely 
ruled monarchy to a socialist state (figure 1). Mapping 
these histories to the discovery curve provides a step 
towards understanding the complexities that shape 
pathogen discovery and modelling the rate of discovery.
The first written French description of a pathogen in 
Laos was in 1874 (a cholera outbreak), recorded in a 1904 
French publication.24 From 1893 the gradual increase in 
grade 3 diagnoses could be ascribed to the expansion of 
early French healthcare and associated clinical descrip-
tions of the diseases encountered. Under French colonial 
rule the numbers of hospitals with medically trained staff 
increased from 0 to 12.13 The French setup basic training 
and medical facilities, including a small bacteriology 
laboratory (in 1924) at Mahosot Hospital, Vientiane.
An increase in laboratory capabilities is matched by a 
decline in the frequency of clinical discovery (grade 3). 
Post-1924 laboratory developments include, enhanced 
microscopical capacities (a grade 1 recognised level of 
evidence) and limited serological testing (grade 2), influ-
encing the shapes of grades 1 and 2 curves, respectively 
(figure 1). During the French colonial occupation of 
Laos, there was a limited rural health worker presence 
and therefore while Laos did have some expertise and 
facilities necessary for aetiological investigation, these 
resources were limited and inaccessible for much of the 
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country.13 French funding and support decreased in the 
mid- 1930s and during World War 2.13 The effects of which 
are reflected in a tapering off of the all- grade discovery 
rates (figure 1). In 1950, control of the health facilities 
was transferred to Lao authorities.
During the postcolonial period the all- grade flattening 
of the discovery curves continued until the late 1960s 
and early 1970s. Early into this period two competing 
forms of nationalism emerged in Laos: the Royal Lao 
Government (RLG) and the prosocialist Pathēt Lao.13 
The Geneva Accords of 1954 were an attempt to bring 
stability to the region through the partitioning of the 
country between these groups.26 However, the inher-
ited health facilities, funding and skills were unevenly 
split between these partitions. The colonial health facil-
ities were transferred to the RLG and complemented 
Figure 2 Discovery curve model for level 1 data and MCMC output the yellow points represent the observed data, the red line 
is the best fitting model and the black lines represent the uncertainty in the model estimates. Underneath the model fit curve 
are a series of histograms which represent the posterior distributions of parameter estimates. The chain output can be seen 
at the bottom of the figure and represent the range of parameter values tested and the number of model iterations. MCMC, 
Markov- Chain- Monte- Carlo.
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by a modest emerging private healthcare sector run by 
RLG staff. Alongside these local health facilities, US and 
Philippino aid- agencies set up a network of rural hospi-
tals and medical dispensaries.13 However, the Pathēt Lao 
was responsible for the majority of the rural areas, where 
they set up a network of rudimentary military health 
facilities.13 Therefore, the flattening of the discovery 
curves in figure 1 likely reflects a decrease in aetiological 
investigation during this period of discord.
An increasing foreign presence and Cold- War conflicts 
amplified the political divisions within Laos and in 
1975, the USA, who had supported the RLG, left Laos. 
Figure 3 Discovery curve model for level 2 data and MCMC output. The yellow points represent the observed data, the red 
line is the best fitting model and the black- lines represent the uncertainty in the model estimates. Underneath the model are a 
series of histograms which represent the posterior distributions of parameter estimates. The chain output can be seen at the 
bottom of the figure and represent the range of parameter values tested and the number of iterations. MCMC, Markov- Chain- 
Monte- Carlo.
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The Pathēt Lao gained political control of the country, 
heralding the socialist period.13 26
A Soviet model of socialism was maintained from 1975 
until the 1990s. The adopted Soviet- model of primary 
healthcare was set up to provide free nationwide health-
care.13 After the regimen change many of the medical 
staff, linked to the RLG, left the country resulting in a 
deficit of already limited skilled medical professionals. 
An increased coverage and centralisation of authority 
tempered by a decreased skills capacity could explain the 
observed more gradual incline in the grade 1 discovery 
curve (figure 1). During the socialist period, the Lao 
government received support from other socialist states. 
As this economic structure began to collapse internation-
ally, so did the support that they provided to nations like 
Laos.
In the 1990s, Laos incorporated elements of free- market 
trade into policy, creating a new era of post- Sovietism.13 26 
Figure 4 Discovery curve model for level 3 data and MCMC output. The yellow points represent the observed data, the red 
line is the best fitting model and the black lines represent the uncertainty in the model estimates. Underneath the model are a 
series of histograms which represent the posterior distributions of parameter estimates. The chain output can be seen at the 
bottom of the figure and represent the range of parameter values tested and the number of iterations. MCMC, Markov- Chain- 
Monte- Carlo.
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Despite these changes, Laos’ contributions to scientific 
literature during the 1990s remained low.27 Investment 
in diagnostic capabilities increased in 1998/1999,13 27 
reflected in the steep incline of grade 1 data (figure 1). 
Since the introduction of PCR assays for patient diagnosis 
in 2006, at Mahosot Hospital, an increasing number of 
human pathogens have been detected by PCR assays 
(figure 1), reflected in a steep incline of grade 1 discovery 
curves in the 2000s.
This changing politics and health of Laos forms a useful 
backdrop for the developed models. In the context of 
Laos narrative the plateauing off of the curves suggests 
that French colonial era years had a limited impact 
on the future discovery rate. However, this era was still 
responsible a large proportion of, mostly clinical, early 
first descriptions of pathogens.
These early clinical descriptions are still important 
as in some instances, for example, Epstein- Barr virus in 
1966 or chicken pox virus in 1927,28 29 they represent the 
only descriptions of the presence of these pathogens in 
Laos. To recognise the importance of these early discov-
eries the models used the grade of evidence to create the 
data subsets (levels) which were then used to inform the 
three models. The discovery curve in model 3 includes 
clinical diagnoses (grade 3) as first descriptions. Clinical 
diagnosis is usually not as definitive as other technolog-
ical advancements. Therefore, model 2 excludes clini-
cally described pathogens as first discoveries. Similarly, 
model 1 excludes serologically or clinically described 
pathogens.
The estimates from the models suggest that between 
11 (level 3), 12 (level 2) and 13 (level 1) new species 
are currently available for discovery in Laos, reflecting 
estimated total species diversity of 169, 185 and 206, 
respectively (table 1). Although 244 descriptions were 
recorded, these included repeat ‘first’ descriptions at 
different grades. These represent 195 different species 
with any grade of positive evidence. As the discovery 
curves used in the models did not permit repetition, 
estimates are expected to be lower than the total 
number of descriptions. A sensitivity analysis shows a 
range of diversity estimates of between: 157–185 for 
level 1, 175–200 for level 2 and 197–221 for level 3. 
Although there are no other estimates with which to 
compare these, this proof of concept provides a basis 
for future evaluation.
The differences in the estimated diversity are greatest 
between the levels 1 and 3 models, due in part to  c  , the 
number of pathogens discovered before 1954. The level 
3 data includes many clinical descriptions that have 
not been described at a higher grade of evidence and 
are subsequently not reflected in the modelled data for 
higher levels. For example, the clinical specificity of 
some diseases, such as rabies, together with the past and 
current aetiological diagnosis limitations of Laos, has 
inhibited the description of their pathogens at higher 
published evidence grade. The history of foreign involve-
ment and dependence has meant that Laos has had a 
limited number of locally trained technically skilled staff 
and necessary diagnostic capabilities for further aetiolog-
ical investigation until ~2000.
Although there is a 16 species difference between the 
level 2 and level 1 models, there is only a difference of 1 
between their baseline  c  value, suggesting that the main 
differences occur in the actual model. Given the current 
capacity for health research in Laos, model 2 (inclusive 
of grade 2 evidence) is likely to represent the expected 
future trajectory in discovery, depending on serological 
Table 1 Summary of estimates and parameter confidence intervals by model
Parameters
Level 1 discovery curve 
model
(Includes only grade 1 
evidence of discovery)
Level discovery curve 
model
(Includes grade 1 or 2 
evidence of discovery)
Level 3 discovery curve 
model
(Includes grade 1, 2 or 3 
evidence of discovery)
Total no of species known in 2017 
(unmodelled)
156 173 195
 c 50 51 74
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diagnosis, unless significant nationwide investment in 
molecular and culture methods are made.
Despite a slight decline in rate of discovery in the second 
decade of this century, the models are not asymptotic, 
suggesting that data informing the model is incomplete 
and/or that the key modelling assumption of a finite 
number of pathogens available for discovery in Laos is not 
met. Accounting for emergent and imported pathogens will 
be crucial for further modelling of these data.
The majority of emergent zoonotic diseases are viral, of 
which there are comparatively fewer recorded discoveries in 
Laos (online supplemental file, table 2).30 Although bats are 
major reservoirs of human disease,31 there are no current 
publications on bat- human pathogens in Laos suggesting a 
possible source of future emergence and discovery.
The gradient change is captured in the model by the param-
eter,  f,  and gives an indication of the recent effort associated 
with pathogen description in Laos. The 34- fold increase in 
the discovery rate over the last 10 years in model 1 (table 1) 
suggests that recent efforts and technological advancements 
have had a significant impact on the discovery of pathogens 
and it will take more infectious disease research before the 
number of pathogens available for discovery saturates.
Important limitations of this study include the exclusion of 
languages other than French and English, and not searching 
archives in Vietnam and Russia. The use and definition of 
species represents difficulty for some pathogens, such as 
for Salmonella enterica that includes both typhoid and non- 
typhoidal Salmonella. This research does not investigate 
the risk of associated morbidity or mortality predicted with 
the emergence of new infections. However, there is poten-
tial to use these data to develop a model that considers the 
evolutionary stages, as identified by Wolfe et al,32 to predict 
if an emergent infection is likely to persist in the population 
causing long term mass morbidity/mortality or is self- limiting 
within human populations.
Despite the recent increase in pathogen discovery rate, 
Laos has among the lowest health- science outputs of coun-
tries in the Association of South East Asian Nations.27 33 
While the 34- fold increase (using model 1 outputs) can be 
attributed to the recent investments in human capacity and 
techniques, these advancements reflect a continued depen-
dence on international collaborations.34 With expenditure 
on health low (2.8% of gross domestic product in 2015), 
the health sector remains underdeveloped for discovery 
and surveillance of new pathogens.35
Despite the uncertainties in the model, the observed 
recent great increase in the discovery rate should inform 
national policy and investment, to understand what human 
pathogens are present, and how much further investment 
in pathogen description is needed, to ensure that strategies 
are in place to protect public health. Accompanying these 
investigations with local historical analysis builds on past 
experience of pathogen discovery to identify factors that 
influence discovery and encourage investment. Compara-
tive country- level historically linked discovery curve inves-
tigations could improve our understanding of diversity 
variability, estimate the probabilities of new descriptions 
and our understanding of the factors influencing such 
discoveries in different health systems.
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